Jonathan Pol
As seen in:
Nature,
Frontiers,
Gut Journal,
The BMJ,
BioRxiv,
Cell Press,
Cell Reports Medicine,
MarketersMedia News
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jonathan Pol
Time-domain NMR enables non-invasive longitudinal monitoring of intrahepatic cholangiocarcinoma in mice
Abstract Intrahepatic cholangiocarcinoma (iCCA) is an aggressive biliary malignancy for which longitudinal non-invasive monitoring remains challenging in preclinical models. Using time-domain nuclear magnetic resonance (TD-NMR), we characterized disease-associated whole-body composition changes in the pNICD/pAKT hydrodynamic injection mouse model of iCCA.
Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directions
Conclusions and future directions It is worth noting that the foundations of modern cancer immunotherapy are rooted in clinical observations correlating antitumor benefits with immunity induced by natural infections. In the late 1890s, Dr William Coley, the father of cancer immunotherapy, discovered that local bacterial infections could halt the advancement of sarcomas in patients.
Acyl-CoA-binding protein (ACBP): a poor-prognosis biomarker in sepsis and a target for disease mitigation
|
Abstract Sepsis remains a major clinical challenge, with high mortality and long-term disability despite current interventions. Here, we identify the tissue hormone acyl-CoA-binding protein (ACBP), also known as diazepam-binding inhibitor (DBI), as a biomarker and driver of poor outcome in sepsis. ACBP/DBI was elevated in the plasma of septic patients and associated with organ dysfunction and increased mortality.
By Flavia Lambertucci, Omar Motiño, Uxia Nogueira-Recalde, Yan Rong, Léa Montégut, Maria Perez-Lanzon, Vincent Carbonnier, Sijing Li, Sylvère Durand, Fanny Aprahamian, Hui Chen, Yanbing Dong, Allan Sauvat, Silvia Mingoia, Sylvie Lachkar, Jonathan Pol, Federico Pietrocola, Maria Chiara Maiuri, Francisco Vasques-Nóvoa, Roberto Lozano-Rodríguez, Jose Avendaño-Ortiz, Eduardo López-Collazo, Mahmoud Abdellatif, Isabelle Martins, Guido Kroemer, Ester Saavedra, Estela Rocha-Oliveira, Roberto Roncon-Albuquerque Jr
|
Nature
Verified
ACBP/DBI neutralization for the prevention and treatment of malignant and non-malignant liver diseases - Cell Death & Disease
Abstract Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI), suppresses autophagy, stimulates food intake, and regulates body composition. This tissue hormone contributes to the development of age-related diseases such as metabolic syndrome, cardiovascular disease, cancer, and osteoarthritis. ACBP/DBI also plays a key pathogenic role in liver disorders, including hepatocellular carcinoma (HCC).
Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma
|
Keywords HCC ACBP/DBI inhibition anti-PD-1 proliferation ferroptosis immunotherapy obesity MASH Introduction Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide,1 is linked to a series of established risk factors that include metabolic dysregulation (such as obesity and diabetes favoring the development of metabolic dysfunction-associated steatohepatitis [MASH] and progression to advanced fibrosis and cirrhosis), repeated insult by hepatotoxins (such as...
By Sijing Li, Omar Motiño, Flavia Lambertucci, Jonathan Pol, Hui Chen, Long Pan, Sylvère Durand, Federica Rossin, Claudia Campani, Lucie Poupel, Christophe Klein, Léa Montégut, Maria Perez-Lanzon, Gerasimos Anagnostopoulos, Uxia Nogueira-Recalde, Alexandra Cerone, Fanny Aprahamian, Yanbing Dong, Manuela Lizarralde-Guerrero, Enfu Xue, Peng Liu, Liwei Zhao, Hui Pan, Vincent Carbonnier, Sylvie Lachkar, Li Sun, Chantal Desdouets, Sabine Colnot, Oliver Kepp, Isabelle Martins, Laurence Zitvogel, Mauro Piacentini, Jean-Charles Nault, Maria Chiara Maiuri, Jessica Zucman-Rossi, Guido Kroemer
|
Cell Reports Medicine
Verified
Lysosomal membrane permeabilization enhances the anticancer effects of RNA Polymerase I transcription inhibitors
Abstract Lysosomes are known to contribute to the development of drug resistance through a variety of mechanisms that include the sequestration of drugs within their compartments and the activation of adaptive stress pathways. Although targeting POL I (RNA polymerase I) exhibits anticancer effects, little attention has been paid to the contribution of lysosomes to the efficacy and resistance of RNA POL I inhibitors.
Epigenetic regulation of HOXA2 expression affects tumor progression and predicts breast cancer patient survival - Cell Death & Differentiation
Abstract Accumulating evidence suggests that genetic and epigenetic biomarkers hold potential for enhancing the early detection and monitoring of breast cancer (BC). Epigenetic alterations of the Homeobox A2 (HOXA2) gene have recently garnered significant attention in the clinical management of various malignancies. However, the precise role of HOXA2 in breast tumorigenesis has remained elusive.
Mast cells and histamine in cholangiocarcinoma: exploring overlooked avenues for enhanced patient management
CHOLANGIOCARCINOMA HISTAMINE MAST CELLS In the realm of cholangiocarcinoma (CCA), a malignancy often presenting with biliary stenosis, the clinical need to re-establish duct patency offers a unique opportunity to profile bile content, facilitating the identification of potential diagnostic and prognostic biomarkers. Various studies have explored the significance of biochemically distinct molecules in the bile of patients with CCA by comparing with healthy or unrelated biliary disorder controls.
PANoptosis-related molecular subtype and prognostic model associated with the immune microenvironment and individualized therapy in pancreatic cancer
Biao Zhang1†, Bingqian Huang1,2†, Xiaonan Zhang1,2†, Shuang Li1, Jingyi Zhu1,2, Xu Chen1*, Huiyi Song1* and Dong Shang1,2* 1Department of General Surgery, Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China 2Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, China Background: PANoptosis is an inflammatory type of programmed cell death regulated by PANopotosome.
Discover the Benefits of All-Natural, Sustainable Home Goods with Pure Wool Dryer Ball
Wyoming, United States - April 6, 2023 /MarketersMEDIA/ — Over the last several years, the popularity of wool dryer balls has exploded, providing consumers with a wealth of options at various price points. Wooly Heroes is one such leading seller of non-toxic linens and laundry accessories, quickly standing apart for its high-quality wool balls featuring hand-stitched animal faces.
Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity
Main Text (Cell Metabolism 30, 754–767.e1–e9; October 1, 2019) In the originally published version of this article, the second and third lanes of the western blot analyses shown in Figure 1A were erroneously labeled. The corrected version of Figure 1A is shown here. This mistake does not affect the conclusions of the paper. The error has now been corrected in the article online. The authors apologize for the error and any inconvenience that may have resulted.
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
Pitt J.M. et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016; 44: 1255-1269 Kroemer G. et al. Natural and therapy-induced immunosurveillance in breast cancer. Nat. Med. 2015; 21: 1128-1138 Chen D.S. Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541: 321-330 Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest. 2015; 125: 3335-3337 Teng M.W. et al.
Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Correction to: Nature Communications https://doi.org/10.1038/s41467-019-09415-3, published online 2 April 2019 The original version of this Article contained an error in the spelling of the author Lin Xia, which was incorrectly given as Xia Lin. This has now been corrected in both the PDF and HTML versions of the Article. Author information Author notes These authors contributed equally: Peng Liu, Liwei Zhao. These authors jointly supervised this work: Oliver Kepp, Guido Kroemer.
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Abstract Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic activity when combined with non-ICD inducing chemotherapeutics like cisplatin.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jonathan
Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack